PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.
about
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?Targeting the innate immune system as immunotherapy for acute myeloid leukemiaTumor infiltrating lymphocytes in ovarian cancerThe PD1:PD-L1/2 Pathway from Discovery to Clinical ImplementationNovel therapeutic options in Acute Myeloid LeukemiaAcid ceramidase is upregulated in AML and represents a novel therapeutic target.The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1.Checkpoint inhibitors in hematological malignanciesNatural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia.Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.Lenalidomide enhances anti-myeloma cellular immunityAlloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanomaBRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.Biochemical signaling of PD-1 on T cells and its functional implicationsImmunotherapy of malignant gliomas using autologous and allogeneic tissue cells.Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.PD-1 regulates extrathymic regulatory T-cell differentiation.Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemiaTargeting CD8+ T-cell tolerance for cancer immunotherapy.PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemiaPast, present and future targets for immunotherapy in ovarian cancerAccumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes.Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy.PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation.Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemiaAn Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia CellsPositive and negative regulation of cellular immune responses in physiologic conditions and diseasesPD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.Programmed death ligand 2 in cancer-induced immune suppression.Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms.PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines
P2860
Q26770391-6D127CE0-CC8A-445F-9E21-674F91C0089FQ27003955-AF2D8091-A5B6-4AFC-B75D-10A4D70ABE16Q27015876-CB0A29F0-4B6F-4509-89FA-DE6BD62534C0Q27021878-CE981F43-9EB9-48D5-8710-83F1D82A29C3Q28066941-826AC1C4-FB8E-4122-9AF7-D6F2425D43D4Q28069889-9EE47593-16FB-4AA6-9858-AB21BB899B78Q30275460-48D5EBAB-D445-4AA5-8AF4-EFB5B4F99472Q33591618-C06B69AF-B790-4FAF-A9DE-C4BA20B57E43Q33651495-1C596B43-84AD-4A3A-A915-695539D0FD65Q33734571-AA1F012F-1E5D-4E1D-B8FF-4E164A085F66Q33814411-E8C01139-4825-4626-B51B-3B297C1BF33DQ33903133-88201774-80B9-4A0A-8D66-F25394BECFA6Q33967995-DF976DD4-8F2A-423B-B90B-2E771B46EE04Q34034408-A3865033-57A4-4F51-97F7-69567BB25A41Q34103836-23A0719D-B0F3-484F-BEE3-B9F0CA409BA0Q34116796-D16832DA-F307-40E9-A5DE-C99F40BBE3EFQ34140756-BB4C46A7-6CDF-48AE-9817-1CA2A9727F78Q34161493-2AAFB142-DC17-4C74-9F3B-B8E0066F6FCEQ34193534-DDC65297-B36D-4E05-B505-2D6F2FFFE58DQ34195209-50DE7206-BE76-4008-90C4-5DA66FC50685Q34245048-8BC7803F-190E-402F-979C-312CCC68526BQ34432692-1524B2CE-C0DC-480F-AA48-ADE546CBEC68Q34557896-C2333ED8-E9B1-4E8E-930B-42CF74D1B9C7Q34715598-1B0CE4C9-F0D9-42D5-AB5D-63899473F3BBQ34997704-084015B8-BAE4-4DED-800C-DE72C267B909Q35034010-51F84134-0C98-429F-A8B3-AF9763F80708Q35036388-DCE6AD91-370B-45EB-A6CC-9D9184E4D36EQ35107621-D04741A9-1189-45BA-90EE-B3076649A4ACQ35128716-45E89711-E2D1-4F98-AEBC-59CBBABECE53Q35196739-ADFC4052-E5C1-443F-BD40-E91F8B2DECAFQ35294382-3149BF9E-3885-489A-8804-0B64AFFA2EA6Q35311785-353F06F1-6907-44C2-985D-36F7080FD8F3Q35553553-DC940794-EAFA-4249-9C32-2DE760E1AD25Q35836860-AF1F1CD4-6954-4DD2-926F-4273E61966DEQ35866682-F5562C65-4F26-49BF-A856-86DF61D81E28Q35883043-59A6F576-DFB9-4C7B-8C79-3416045165DCQ35921900-DF634A5D-0695-4850-9151-FF4F2996AB88Q35955151-5BA2949C-4BB1-4A3D-8483-52ECB48A317EQ36067524-FFDB45E6-263F-4EBF-B2B8-426BC581C379Q36220691-225E2DC9-B354-4B67-B864-92D1A8A30C78
P2860
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PD-1/PD-L1 interactions inhibi ...... acute myeloid leukemia model.
@en
PD-1/PD-L1 interactions inhibi ...... acute myeloid leukemia model.
@nl
type
label
PD-1/PD-L1 interactions inhibi ...... acute myeloid leukemia model.
@en
PD-1/PD-L1 interactions inhibi ...... acute myeloid leukemia model.
@nl
prefLabel
PD-1/PD-L1 interactions inhibi ...... acute myeloid leukemia model.
@en
PD-1/PD-L1 interactions inhibi ...... acute myeloid leukemia model.
@nl
P2093
P2860
P1433
P1476
PD-1/PD-L1 interactions inhibi ...... acute myeloid leukemia model.
@en
P2093
Justin Kline
Long Zhang
Thomas F Gajewski
P2860
P304
P356
10.1182/BLOOD-2009-03-206672
P407
P577
2009-05-05T00:00:00Z